Microbiological Profiles and Resistance Patterns in Pediatrics With Cancer: An 8-Year Study at a Comprehensive Cancer Center in Jordan

约旦一家综合癌症中心开展的一项为期8年的儿科癌症患者微生物学特征和耐药模式研究

阅读:1

Abstract

INTRODUCTION: Infections impact morbidity and mortality in pediatric cancer patients, yet limited studies have assessed the microbiological profiles and susceptibility patterns of pathogenic bacteria in this population. This study aimed to investigate bacterial profiles and temporal resistance changes in pediatrics with cancer. METHODS: We identified positive cultures between January 2015 and December 2022 for pediatric patients diagnosed with cancer at age < 18 years. Electronic records provided patient demographics, microbiological profiles and resistance patterns. Using "R" programming, the dataset was refined, selecting patients' first isolate within a 30-day period, and categorizing strains based on multidrug-resistant (MDR) and extensively drug-resistant (XDR) predefined criteria. Additionally, we analyzed changes in resistance patterns over the study period. RESULTS: Out of 1215 patients, 2992 bacterial isolates were reported, with 66% being Gram-negative bacteria. Urine was the most common site of infection, representing 48% of cases. Among these, 42% were MDR and 2% XDR. MDR prevalence was 45% for Escherichia coli, 21% for Klebsiella pneumonia, and 14% for Staphylococcus aureus. Acinetobacter baumannii and Pseudomonas aeruginosa displayed XDR at 79% and 21%, respectively. Methicillin-resistant S. aureus decreased from 71% in 2015 to 54% in 2022. MDR Klebsiella pneumonia peaked in 2021. MDR Pseudomonas aeruginosa decreased from 44% in 2015 to 16% in 2022. CONCLUSION: Drug resistance was detected in 50% of the isolates with most being Gram-negative and MDR. Further research is needed to identify risk factors for resistance, aiming to refine empiric antimicrobial therapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。